Foundation Fighting Blindness

• Eye on the Cure Podcast | Episode 87: Dr. Philip Beales

  June 13, 2025. Dr. Philip Beales, a co-founder of Axovia Therapeutics, talks to host Ben Shaberman about Bardet Biedl syndrome, ciliopathies, and his company's emerging gene therapy for Bardet Biedl syndrome type 1 (BBS1) which is moving toward a clinical trial.

  --------  

  18:54

  --------

  18:54
• Eye on the Cure Podcast | Episode 86: Lenore von Krusenstiern, MD, PhD

  May 23, 2025. Lenore von Krusenstiern, MD, PhD, at BlueRock Therapeutics talks to host Ben Shaberman about the company's clinical trial for a photoreceptor replacement therapy for people with inherited retinal conditions such as retinitis pigmentosa and cone-rod dystrophy. The approach, which uses induced pluripotent stem cells to develop photoreceptor precursors, comes out of the lab of stem cell pioneer David Gamm, MD, PhD, University of Wisconsin-Madison.

  --------  

  31:15

  --------

  31:15
• J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial

  Despite missing the primary endpoint, the treatment improved vision for some patients.

  --------  

  2:35

  --------

  2:35
• ARVO 2025 Highlight: PYC Reports Encouraging Phase 1/2 Clinical Trial Results for its RNA Therapy Targeting RP (PRPF31 Mutations)

  The company is planning a Phase 2/3 clinical trial for therapy in late 2025.

  --------  

  4:53

  --------

  4:53
• ARVO 2025 Highlight: Atsena’s XLRS Gene Therapy Provides Vision and Structural Improvements in Phase 1/2 Clinical Trial

  Part B of the trial will enroll nine adult patients as well as three pediatric patients.

  --------  

  4:15

  --------

  4:15

More Science podcasts

Trending Science podcasts

About Foundation Fighting Blindness